The clinical approach to lung disease in patients with cystic fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 30, Issue 5, 2009, Pages 505-513

  O'Sullivan, Brian P ^a   Flume, Patrick ^b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Antibiotic therapy; Cystic fibrosis; Inflammation; Pathogenesis; Prophylaxis; Treatment

Indexed keywords

AMINOCAPROIC ACID; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; CEFALEXIN; COLISTIN; DORNASE ALFA; FLUCOXACILLIN; IBUPROFEN; SALBUTAMOL; SODIUM CHLORIDE; STEROID; TOBRAMYCIN; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; BREATHING EXERCISE; COMPUTER ASSISTED TOMOGRAPHY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; GRAM NEGATIVE INFECTION; HUMAN; INFLAMMATION; LUNG CLEARANCE; LUNG DISEASE; LUNG INFECTION; PATHOGENESIS; PATIENT CARE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; THORAX RADIOGRAPHY;

CYSTIC FIBROSIS; HUMANS; LUNG DISEASES; PERSONAL AUTONOMY; PRACTICE GUIDELINES AS TOPIC; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; RESPIRATORY THERAPY; RESPIRATORY TRACT INFECTIONS;

EID: 70350469120     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0029-1238909     Document Type: Review

References (94)

1. O'Sullivan B P., Freedman S D. Cystic fibrosis. Lancet 2009 373 1891-1904
2. Carlson D, McKeen E, Mitchell M et al. Oropharyngeal flora in healthy infants: observations and implications for cystic fibrosis care. Pediatr Pulmonol 2009 44 497-502
3. Sagel S D., Gibson R L., Emerson J et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009 154 183-188
4. Fuchs H J., Borowitz D S., Christiansen D H. et al, The Pulmozyme Study Group. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994 331 637-642
5. Hartl D, Latzin P, Hordijk P et al. Cleavage of CXCR1 on neutrophils disables bacterial killing in cystic fibrosis lung disease. Nat Med 2007 13 1423-1430
6. Farrell P M., Li Z, Kosorok M R. et al. Longitudinal evaluation of bronchopulmonary disease in children with cystic fibrosis. Pediatr Pulmonol 2003 36 230-240 (Pubitemid 37055971)
7. Armstrong D S., Grimwood K, Carzino R, Carlin J B., Olinsky A, Phelan P D. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis. BMJ 1995 310 1571-1572
8. Linnane B M., Hall G L., Nolan G et al, AREST-CF. Lung function in infants with cystic fibrosis diagnosed by newborn screening. Am J Respir Crit Care Med 2008 178 1238-1244
9. Khan T Z., Wagener J S., Bost T, Martinez J, Accurso F J., Riches D W. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995 151 1075-1082
10. Konstan M W., Butler S M., Wohl M EB et al, Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003 142 624-630
11. Padman R, McColley S A., Miller D P. et al, Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Infant care patterns at epidemiologic study of cystic fibrosis sites that achieve superior childhood lung function. Pediatrics 2007 119 e531-e537
12. Campbell P W. III, Parker R A., Roberts B T., Krishnamani M RS, Phillips J A. III. Association of poor clinical status and heavy exposure to tobacco smoke in patients with cystic fibrosis who are homozygous for the F508 deletion. J Pediatr 1992 120 (2 Pt 1) 261-264
13. Johnson C, Butler S M., Konstan M W., Morgan W, Wohl M EB. Factors influencing outcomes in cystic fibrosis: a center-based analysis. Chest 2003 123 20-27
14. Flume P A., Robinson K A., O'Sullivan B P. et al, Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care 2009 54 522-537
15. Lester M K., Flume P A. Airway clearance therapy guidelines and implementation. Respir Care 2009 54 733-750
16. Button B M., Heine R G., Catto-Smith A G. et al. Chest physiotherapy in infants with cystic fibrosis: to tip or not? A five-year study. Pediatr Pulmonol 2003 35 208-213
17. Donaldson S H., Bennett W D., Zeman K L., Knowles M R., Tarran R, Boucher R C. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006 354 241-250
18. Ratjen F. Restoring airway surface liquid in cystic fibrosis. N Engl J Med 2006 354 291-293
19. Robinson M, Hemming A L., Regnis J A. et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997 52 900-903
20. Elkins M R., Robinson M, Rose B R. et al, National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006 354 229-240
21. Flume P A., O'Sullivan B P., Robinson K A. et al, Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007 176 957-969
22. Robinson M, Daviskas E, Eberl S et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999 14 678-685
23. Jaques A, Daviskas E, Turton J A. et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008 133 1388-1396
24. McCoy K, Hamilton S, Johnson C, Pulmozyme Study Group. Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Chest 1996 110 889-895
25. Grasemann H, Lax H, Treseler J W., Colin A A. Dornase alpha and exhaled NO in cystic fibrosis. Pediatr Pulmonol 2004 38 379-385
26. Quan J M., Tiddens H A., Sy J P. et al, Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001 139 813-820
27. Nasr S Z., Kuhns L R., Brown R W., Hurwitz M E., Sanders G M., Strouse P J. Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study. Pediatr Pulmonol 2001 31 377-382
28. Subbarao P, Balkovec S, Solomon M, Ratjen F. Pilot study of safety and tolerability of inhaled hypertonic saline in infants with cystic fibrosis. Pediatr Pulmonol 2007 42 471-476
29. Anon. 2006 Annual Data Report to the Center Directors. Bethesda, MD CF Foundation 2007
30. Sawicki G S., Rasouliyan L, Pasta D J. et al, Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008 43 1117-1123
31. Dasenbrook E C., Merlo C A., Diener-West M, Lechtzin N, Boyle M P. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008 178 814-821
32. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson R L. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002 34 91-100
33. Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995 19 10-15
34. Winnie G B., Cowan R G. Respiratory tract colonization with Pseudomonas aeruginosa in cystic fibrosis: correlations between anti- Pseudomonas aeruginosa antibody levels and pulmonary function. Pediatr Pulmonol 1991 10 92-100
35. Ballmann M, Rabsch P, von der Hardt H. Long-term follow up of changes in FEV1 and treatment intensity during Pseudomonas aeruginosa colonisation in patients with cystic fibrosis. Thorax 1998 53 732-737
36. Nixon G M., Armstrong D S., Carzino R et al. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. J Pediatr 2001 138 699-704
37. Konstan M W., Morgan W J., Butler S M. et al, Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007 151 134-139, 139, e1
38. Beardsmore C S., Thompson J R., Williams A et al. Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment. Arch Dis Child 1994 71 133-137
39. Weaver L T., Green M R., Nicholson K et al. Prognosis in cystic fibrosis treated with continuous flucloxacillin from the neonatal period. Arch Dis Child 1994 70 84-89
40. Stutman H R., Lieberman J M., Nussbaum E, Marks M I. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002 140 299-305
41. Döring G, Conway S P., Heijerman H G. et al. Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J 2000 16 749-767
42. Heinzl B, Eber E, Oberwaldner B, Haas G, Zach M S. Effects of inhaled gentamicin prophylaxis on acquisition of Pseudomonas aeruginosa in children with cystic fibrosis: a pilot study. Pediatr Pulmonol 2002 33 32-37
43. Ratjen E, Munck A, Campello V. Safety of inhaled tobramycin nebuliser solution for treatment of early Pseudomonas aeruginosa infection: first results from the ELITE study [abstract]. J Cyst Fibros 2006 5 S22
44. Ratjen F. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis. Curr Opin Pulm Med 2006 12 428-432
45. Treggiari M M., Rosenfeld M, Retsch-Bogart G, Gibson R, Ramsey B. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007 42 751-756
46. Burns J L., Gibson R L., McNamara S et al. Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis. J Infect Dis 2001 183 444-452
47. Ramsey B W., Dorkin H L., Eisenberg J D. et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993 328 1740-1746
48. Eigen H, Rosenstein B J., FitzSimmons S, Schidlow D V., Cystic Fibrosis Foundation Prednisone Trial Group. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995 126 515-523
49. Balfour-Lynn I M., Lees B, Hall P et al, CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006 173 1356-1362
50. Ren C L., Pasta D J., Rasouliyan L, Wagener J S., Konstan M W., Morgan W J., Scientific Advisory Group and the Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Relationship between inhaled corticosteroid therapy and rate of lung function decline in children with cystic fibrosis. J Pediatr 2008 153 746-751
51. Balfour-Lynn I M., Lees B, Hall P et al, CF WISE (Withdrawal of Inhaled Steroids Evaluation) Investigators. Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med 2006 173 1356-1362
52. Chmiel J F., Konstan M W. Inflammation and anti-inflammatory therapies for cystic fibrosis. Clin Chest Med 2007 28 331-346
53. Konstan M W., Byard P J., Hoppel C L., Davis P B. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995 332 848-854
54. Lands L C., Milner R, Cantin A M., Manson D, Corey M. High-dose ibuprofen in cystic fibrosis: Canadian safety and effectiveness trial. J Pediatr 2007 151 249-254
55. Fennell P B., Quante J, Wilson K, Boyle M, Strunk R, Ferkol T. Use of high-dose ibuprofen in a pediatric cystic fibrosis center. J Cyst Fibros 2007 6 153-158
56. Idris S F., Chilvers E R., Haworth C, McKeon D, Condliffe A M. Azithromycin therapy for neutrophilic airways disease: myth or magic? Thorax 2009 64 186-189
57. Köhler T, Dumas J-L, Van Delden C. Ribosome protection prevents azithromycin-mediated quorum-sensing modulation and stationary-phase killing of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2007 51 4243-4248
58. Koyama H, Geddes D M. Erythromycin and diffuse panbronchiolitis. Thorax 1997 52 915-918
59. Ordoñez C L., Stulbarg M, Grundland H, Liu J T., Boushey H A. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study. Pediatr Pulmonol 2001 32 29-37
60. Equi A, Balfour-Lynn I M., Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002 360 978-984
61. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002 57 212-216
62. Saiman L, Marshall B C., Mayer-Hamblett N et al, Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003 290 1749-1756
63. Block J K., Vandemheen K L., Tullis E et al. Predictors of pulmonary exacerbations in patients with cystic fibrosis infected with multi-resistant bacteria. Thorax 2006 61 969-974
64. Goss C H., Burns J L. Exacerbations in cystic fibrosis, I: Epidemiology and pathogenesis. Thorax 2007 62 360-367
65. Bell S C., Robinson P J. Exacerbations in cystic fibrosis, II: Prevention. Thorax 2007 62 723-732
66. Smyth A, Elborn J S. Exacerbations in cystic fibrosis, III: Management. Thorax 2008 63 180-184
67. Anderson D H. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child 1938 56 344
68. Szaff M, Høiby N, Flensborg E W. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983 72 651-657
69. Regelmann W E., Elliott G R., Warwick W J., Clawson C C. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990 141 (4 Pt 1) 914-921
70. Wolter J M., Bowler S D., Nolan P J., McCormack J G. Home intravenous therapy in cystic fibrosis: a prospective randomized trial examining clinical, quality of life and cost aspects. Eur Respir J 1997 10 896-900
71. Proesmans M, Heyns L, Moons P, Havermans T, De Boeck K. Real life evaluation of intravenous antibiotic treatment in a paediatric cystic fibrosis centre: outcome of home therapy is not inferior. Respir Med 2009 103 244-250
72. Yi M S., Tsevat J, Wilmott R W., Kotagal U R., Britto M T. The impact of treatment of pulmonary exacerbations on the health-related quality of life of patients with cystic fibrosis: does hospitalization make a difference? J Pediatr 2004 144 711-718
73. Nazer D, Abdulhamid I, Thomas R, Pendleton S. Home versus hospital intravenous antibiotic therapy for acute pulmonary exacerbations in children with cystic fibrosis. Pediatr Pulmonol 2006 41 744-749
74. Thornton J, Elliott R, Tully M P., Dodd M, Webb A K. Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis. Thorax 2004 59 242-246
75. Jones A M., Dodd M E., Govan J RW et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004 59 948-951
76. Kalish L A., Waltz D A., Dovey M et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006 173 421-425
77. Burns J LMD, Saiman L MD. Burkholderia cepacia infections in cystic fibrosis. Pediatr Infect Dis J 1999 18 155-156
78. Aaron S D., Ferris W, Henry D A., Speert D P., Macdonald N E. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000 161 (4 Pt 1) 1206-1212 (Pubitemid 30243831)
79. Stevens D A., Moss R B., Kurup V P. et al, Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosisstate of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003 37 (Suppl 3) S225-S264
80. Mastella G, Rainisio M, Harms H K. et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis: a European epidemiological study. Epidemiologic Registry of Cystic Fibrosis. Eur Respir J 2000 16 464-471
81. Skov M, Høiby N, Koch C. Itraconazole treatment of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Allergy 2002 57 723-728
82. Ibrahim W H. Massive haemoptysis: the definition should be revised. Eur Respir J 2008 32 1131-1132
83. Wong L TK, Lillquist Y P., Culham G, DeJong B P., Davidson A GF. Treatment of recurrent hemoptysis in a child with cystic fibrosis by repeated bronchial artery embolizations and long-term tranexamic acid. Pediatr Pulmonol 1996 22 275-279
84. Brinson G M., Noone P G., Mauro M A. et al. Bronchial artery embolization for the treatment of hemoptysis in patients with cystic fibrosis. Am J Respir Crit Care Med 1998 157 (6 Pt 1) 1951-1958
85. Furnari M L., Salerno S, Rabiolo A, Caravello V, Pardo F. Bronchial to subclavian shunt in a CF patient: a potential pitfall for embolization. J Cyst Fibros 2003 2 217-219
86. Flume P A. Pneumothorax in cystic fibrosis. Chest 2003 123 217-221
87. Phillips G D., Trotman-Dickenson B, Hodson M E., Geddes D M. Role of CT in the management of pneumothorax in patients with complex cystic lung disease. Chest 1997 112 275-278
88. Davis P B., di Sant'Agnese P A. Assisted ventilation for patients with cystic fibrosis. JAMA 1978 239 1851-1854
89. Slieker M G., van Gestel J P., Heijerman H G. et al. Outcome of assisted ventilation for acute respiratory failure in cystic fibrosis. Intensive Care Med 2006 32 754-758
90. Sood N, Paradowski L J., Yankaskas J R. Outcomes of intensive care unit care in adults with cystic fibrosis. Am J Respir Crit Care Med 2001 163 335-338
91. Young A C., Wilson J W., Kotsimbos T C., Naughton M T. Randomised placebo controlled trial of non-invasive ventilation for hypercapnia in cystic fibrosis. Thorax 2008 63 72-77
92. Serra A, Polese G, Braggion C, Rossi A. Non-invasive proportional assist and pressure support ventilation in patients with cystic fibrosis and chronic respiratory failure. Thorax 2002 57 50-54
93. Kramer J M. Balancing the benefits and risks of inhaled long-acting beta-agoniststhe influence of values. N Engl J Med 2009 360 1592-1595
94. Drazen J M., O'Byrne P M. Risks of long-acting beta-agonists in achieving asthma control. N Engl J Med 2009 360 1671-1672